Gene-environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis

Thrombosis and Haemostasis

Volumn 78, Issue 1, 1997, Pages 457-461

  Humphries, S E ^a,c   Panahloo, A ^b   Montgomery, H E ^a   Green, F ^a   Yudkin, J ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b WHITTINGTON HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FIBRINOGEN; LIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ACUTE PHASE RESPONSE; CONFERENCE PAPER; CONGENITAL DISORDER; DIABETES MELLITUS; ENDOTHELIUM CELL; ENVIRONMENTAL FACTOR; EXERCISE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; GENE SEQUENCE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HEMOSTASIS; HEREDITY; HIGH RISK POPULATION; HUMAN; INFLAMMATION; LIPID BLOOD LEVEL; LIVER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; SMOKING; THROMBOSIS; TISSUE INJURY; TRANSCRIPTION REGULATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030805620     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657569     Document Type: Conference Paper

References (35)

1. Roy S.N., Mukhopadhyay G, Redman CM. Regulation of fibrinogen assembly. Transfection of HepG2 cells with Bß cDNA specifically enhances synthesis of the three component chains of fibrinogen. J Biol Chem 1990; 265: 6389-6393.
2. Dalmon J., Laurent M, Courtios G. The human b fibrinogen promoter contains a hepatocyte nuclear factor 1-dependent interleukin-6 responsive element. Mol Cell Biol 1993; 13: 1183-1193.
3. Thomas A., Kelleher C, Green F, Meade TW, Humphries SE. Variation in the promoter region of the β-fibrinogen gene is associated with plasma fibrinogen levels in smokers and non-smokers. Thromb Haemost 1991; 65: 487-490.
4. Conner J.M., Fowkes FGR, Wood J, Smith FB, Donnon PT, Lowe GDO. Genetic variation at fibrinogen loci and plasma fibrinogen levels. J Med Genet 1992; 29: 480-482.
5. Green F., Hamsten A, Blomback M, Humphries S. The role of b-fibrinogen genotype in determining plasma fibrinogen levels in young survivors of myocardial infarction and healthy controls from Sweden. Thromb Haemost 1993; 70: 915-920.
6. Scarabin P-Y., Bara L, Ricard S, Poirer O, Cambou JP, Arveiler D, Luc G, Evans AE, Samama MM, Cambien F. Genetic variation at the β-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of mtocardial infarction. The ECTIM Study. Arterios Thromb 1993; 13: 886-891.
7. 455 -A β-gene) is associated with differences in plasma fibrinogen levels in young men and women from different regions in Europe: Evidence for gender - genotype - environment interaction. Arterioscler Thromb Vasc Biol 15:96-104.
8. Iso H., Folsom A, Winklemann JC, Koike K, Harada S, Greenberg B, Sato S, Shimamoto T, Lida M, Komachi. Polymorphisms of the beta fibrinbogen gene and plasma fibrinogen concentration in Caucasian and Japanese population samples. Thromb Haemost 1995; 73: 106-111
9. Heinrich J., Funke H, Rust S, Schulte H, Schonfeld R, Kohler E, Assman G. Impact of polymorphisms in the alpha- and beta-fibrinogen gene on plasma fibrinogen concentrations of coronary heart disease patients. Thromb Res 1995; 77: 209-215.
10. -455 polymorphism, age smoking. Clin Genet 1996; 50: 184-190.
11. Humphries S.E., Green F, Thomas A, Montgomery HE, Winder A, Hamsten A, Miller G. Gene-environment interaction in the determination of plasma fibronogen levels. Fibrinolysis 1996; 10: in press.
12. Meade T.W., Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Hemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-537.
13. Lane A., Humphries SE, Green FR. Effect on transcription of two common genetic polymorphism adjacent to the promoter region of the B-fibrinogen gene. Thromb Haemost 1993; 69: 1539.
14. -1689 (AvaII), and BcII (b-fibrinogen) and TaqI (a-fibrinogen), and their detection by PCR. Hum Mutat 1994; 3: 79-81.
15. Montgomery H.E., Clarkson P, Nwose OM, Mikalidis DP, Jagroop IA, Dollery C, Moult J, Benhizia F, Deanfield J, Jubb C, World M, McEwan JR, Winder A, Humphries S. The acute rise in serum fibrinogen concentration with exercise is influenced by the G-453-A polymorphism of the beta-fibrinogen gene. - Arterioscler Thromb Vasc Biol 1996; 16: 386-391.
16. Haines A.P., Howarth D, North WRS, Goldenberg E, Stirling Y, Meade TW, Raftery EB, Craig MWM. Haemostatic variables and outcome of acute myocardial infarction. Thromb Haemost 1983; 50: 800-803.
17. Dawson S., Henney A. The status of PAI-1 as a risk factor for arterial and thrombotic disease: A review. Atherosclerosis 1992; 95: 195-117.
18. Hamsten A., Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator inhibitor in young survivors of myocardial infarction. New Eng J Med 1985; 313: 1557-63.
19. Emeis J., Kooistra T. Interleukin-1 and lipopolysaccharide induce a fast acting inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986; 163: 1260-66.
20. Lund L., Riccio A, Andreasen P, Nielson L, Kristensen P, Lailho M, Saksela O, Blasi F, Dano K. Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. EMBO J 1987; 6: 1281-1286.
21. Alessi M., Juhan-Vague I, Kooistra T, Declerck P, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor-1 by the human hepatocellular cell line HepG2. Thromb Haemost 1988; 60: 491-94.
22. Lucore C., Fuji S, Wun T, Sobel B, Billadello J. Regulation of the expression of type 1 plasminogen activator inhibitor in HepG2 cells by epidermal growth factor. J Biol Chem 1988; 263: 15845-15848.
23. Riccio A., Lund L, Sartorio R, Lania A, Andreasen P, Danf K, Blast F. The regulatory region of the human plasminogen activator inhibitor type-1 gene. Nucl Acid Res 1988; 16:2805-24.
24. Stiko-Rahm A., Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor-1 from human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990; 10: 1067-1073.
25. De Boer J., Abbnik J, Brouwer M, Meijer C, Roem D, Voorn G, Lanbers J, Van Mourik J, Hark C. PAI-1 synthesis in the human hepatoma cell line HepG2 is increased by cytokines -evidence that the liver contributes to acute phase behaviour of PAI-1. Thromb Haemost 1991; 65: 181-187.
26. Dawson S.J., Wiman B, Hamsten A, Green F, Humphries S, Henney A. The two allele sequences of a common polymorphisms in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to IL-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-10745.
27. Eriksson P., Kallin B, Van't Hooft FM, Bavenholm P, Hamsten A. Allele specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Nat Acad Sci USA 1995; 92: 1851-1855.
28. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE, Evans A, Luc G, Cambou JP, Arveiler D, Henney AM, Cambien F. (1995) The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 74 (3) 837-841.
29. Mansfield M.W., Stickland MH, Grant PL. Plasminongen activator inhibitor-1 (PAI-1) promoter polymorphism and coromary artery dsiease in non-insulin-dependent diabetes. Thromb Haemost 1995; 74: 1032-1034.
30. Ossei-Gerning N., Mansfield MW, Stickland MH, Wilson JJ, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and levels in relation to a history of myocardial infarction in patients characterised by coronary angiography. Arterioscler Thromb Vasc Biol 1996; (in press).
31. Juhan-Vague I., Alessi MC, Badier C, Valadier J, Ailaud MF, Atlan C. Relationship between plasma insulin, triglyceride, body mass index and plasminogen activator inhibitor-1. Diabete Metab 1987; 13:331-336.
32. Juhan-Vague I., Alessi M, Joly P, Thirion X, Vague P, Declerck P, Serrodinugni A, Collen D. Plasma plasminogen activator inhibitor 1 in angina pectoris: Influence of plasma insulin and acute phase response. Arterioscler Thromb 1989; 9: 362-367.
33. Panahloo A., Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS. Determinants of plasminogen activator inhibitor 1 activity in treated NIDMM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995; 44:37-42.
34. Mansfield M.W., Stickland MH, Grant PL. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin dependent diabetes. Thromb Haemost 1995; 74: 842-847.
35. Sironi L., Mussoni L, Prati M, Baldassarre D, Camera M, Banfi C, Tremoli E, Plasminongen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL. Arterioscler Thromb Vasc Biol 1996; 16; 89-96.